Related Experiment Video

Updated: May 21, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Genetic risk factors for thrombosis in systemic lupus erythematosus

Rachel Kaiser1, Yonghong Li, Monica Chang

  • 1UCSF Division of Rheumatology, San Francisco, CA 94143, USA.

The Journal of Rheumatology
|June 19, 2012
PubMed

Insights

Genetic variants in Factor V Leiden, MTHFR, and FGG are associated with thrombosis risk in systemic lupus erythematosus (SLE) patients. These genetic associations for thrombosis differ across ethnic groups.

Area of Science:

  • Genetics
  • Rheumatology
  • Vascular Medicine

Background:

  • Thrombosis is a significant complication in systemic lupus erythematosus (SLE).
  • Understanding the genetic underpinnings of thrombosis in SLE is crucial for risk stratification.

Purpose of the Study:

  • To investigate the association between genetic variants in thrombosis pathways and the occurrence of thrombosis in two ethnically diverse SLE cohorts.
  • To identify specific genetic risk factors for thrombosis in patients with SLE.

Main Methods:

  • Utilized discovery (n=1698) and replication (n=1361) SLE cohorts meeting American College of Rheumatology criteria.
  • Genotyped 33 single nucleotide polymorphisms (SNPs) associated with thrombosis risk or pathways.
  • Performed bivariate and multivariable logistic regression analyses, adjusting for clinical factors.

Main Results:

  • Factor V Leiden (FVL) rs6025 and methylenetetrahydrofolate reductase (MTHFR) rs1801133 showed associations with thrombosis risk in white SLE patients.
  • Fibrinogen gamma (FGG) rs2066865 was associated with thrombosis risk in Hispanic American SLE patients.
  • Specific SNPs in FVL, MTHFR, and FGG demonstrated associations with venous and arterial thrombosis risk, varying by ethnicity.

Conclusions:

  • Specific genetic risk factors are implicated in thrombosis development among SLE patients.
  • The genetic predisposition to thrombosis in SLE appears to differ across ethnic populations.
Abstract

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...